DelveInsight’s “Ocular Inflammation and Pain Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Ocular Inflammation and Pain market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The report covers emerging Ocular Inflammation and Pain drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Ocular Inflammation and Pain treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Ocular Inflammation and Pain: An Overview
Eye inflammation occurs in response to infection, allergies, autoimmune disorders, irritation, injury, or trauma to the eyes, eyelids, or surrounding tissues. Different parts of the eye can be affected, depending on the cause of the inflammation.
Types of inflammatory diseases in the eyes include Uveitis, Keratitis, Conjunctivitis, Thyroid Eye Disease, etc. The goal of treatment is to treat the inflammation and check the eyes regularly to help prevent damage and vision loss. The symptoms of eye inflammation depend on the part of the eye that is affected. Scleritis will produce symptoms, such as pain, redness, and watering.
To make an accurate diagnosis, a series of tests will be performed and these typically include a thorough evaluation of the condition, a review of the patient’s medical history, and a comprehensive physical examination to check for any visual evidence of inflammation. Other laboratory tests will also be performed to determine possible causes, such as infections or autoimmune disorders. Meanwhile, the eyes will be checked through various eye tests, such as an eye chart or visual acuity test, an ocular pressure test, a slit lamp test, and a funduscopic exam.
Pain associated with surgery, injury, infection, or inflammation at the front of the eye is typically treated with a topical steroid, topical NSAID, systemic NSAID, lubricant ointment, gel or drops, bandage contact lens, or a few doses of oral opiate or topical anesthetic.
The currently FDA-approved treatments for ocular inflammation and pain include Dextenza and Lotemax SM.
Ocular Inflammation and Pain Market Key Facts
Uveitis can occur in all age groups. Many studies have previously demonstrated a high incidence of uveitis in the working age groups (20–50 years). Thorne et al. (2016) showed that non-infectious uveitis increases with age.
As per Majid et al. (2022), the proportion of females with ocular neuropathic pain is higher than men Females also tend to have a higher incidence of associated conditions such as fibromyalgia and autoimmune diseases. While autoimmune diseases affect between 5 to 8% of the population, 78% of the affected are women. This association may contribute to the higher incidence of ocular neuropathic pain in women.
In a US population-based study, 2482 volunteers aged 65 to 84 years were asked about self-reported frequency of dryness, grittiness, and burning. Among these individuals, 22% reported dryness, 33% grittiness, and 25% burning sometimes, often, or all the time.
the study by Thorne et al. (2016), 56.8% of adult patients with non-infectious uveitis were female.
Ocular Inflammation and Pain Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Ocular Inflammation and Pain pipeline therapies. It also thoroughly assesses the Ocular Inflammation and Pain market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete details of the market trend for each marketed Ocular Inflammation and Pain drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Ocular Inflammation and Pain Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Ocular Inflammation and Pain epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Ocular Inflammation and Pain epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Ocular Inflammation and Pain Epidemiology, Segmented as –
Total Prevalent Cases of Ocular Inflammation and Pain
Gender-specific Prevalent Cases of Ocular Inflammation and Pain
Type-specific Cases of Ocular Inflammation and Pain
Diagnosed and Treatable cases of Ocular Inflammation and Pain
Ocular Inflammation and Pain Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Ocular Inflammation and Pain market or expected to be launched during the study period. The analysis covers the Ocular Inflammation and Pain market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Ocular Inflammation and Pain drugs based on their sale and market share.
The report also covers the Ocular Inflammation and Pain pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Ocular Inflammation and Pain companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Ocular Inflammation and Pain Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/ocular-inflammation-and-pain-market
Ocular Inflammation and Pain Therapeutics Analysis
Approaches to the treatment of ocular pain come from the fields of neuroscience, neurology, and pain management rather than the field of ophthalmology. Most cases of eye inflammation can be successfully treated. However, in rare cases, there can be a serious disease present, which is a threat to the eyesight. Early diagnosis is very important. Some of the drugs approved recently for the treatment of ocular pain and inflammation include Dextenza and Lotemax SM.
To further improve the treatment scenario, several key players are involved in developing therapies for ocular inflammation and pain. Currently, Formosa Pharmaceuticals is leading the therapeutics market with its Ocular Inflammation and Pain drug candidates in the most advanced stage of clinical development.
Ocular Inflammation and Pain Companies Actively Working in the Therapeutics Market Include
Formosa Pharmaceuticals, Inc.
Sun Pharma Advanced Research Company Limited
A.T. Resolve SARL
Tarsius Pharma
SALVAT
And Many Others
Emerging and Marketed Ocular Inflammation and Pain Therapies Covered in the Report Include:
APP13007: Formosa pharmaceuticals
SDN-037: Visiox Pharma LLC/SPARC
DexaSite (ISV-305): InSite Vision/Sun Pharmaceutical Industries
And Many More
Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Ocular Inflammation and Pain Competitive Intelligence Analysis
4. Ocular Inflammation and Pain Market Overview at a Glance
5. Ocular Inflammation and Pain Disease Background and Overview
6. Ocular Inflammation and Pain Patient Journey
7. Ocular Inflammation and Pain Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Ocular Inflammation and Pain Treatment Algorithm, Current Treatment, and Medical Practices
9. Ocular Inflammation and Pain Unmet Needs
10. Key Endpoints of Ocular Inflammation and Pain Treatment
11. Ocular Inflammation and Pain Marketed Therapies
12. Ocular Inflammation and Pain Emerging Drugs and Latest Therapeutic Advances
13. Ocular Inflammation and Pain Seven Major Market Analysis
14. Attribute Analysis
15. Ocular Inflammation and Pain Market Outlook (In US, EU5, and Japan)
16. Ocular Inflammation and Pain Companies Active in the Market
17. Ocular Inflammation and Pain Access and Reimbursement Overview
18. KOL Views on the Ocular Inflammation and Pain Market
19. Ocular Inflammation and Pain Market Drivers
20. Ocular Inflammation and Pain Market Barriers
21. Appendix
22. DelveInsight Capabilities
23. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Request the Sample PDF to Learn More About the Key Offerings of the Report @
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
Chemotherapy Induced Nausea and Vomiting Market
“Chemotherapy Induced Nausea and Vomiting Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Chemotherapy Induced Nausea and Vomiting market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Chemotherapy Induced Nausea and Vomiting market.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Shruti ThakurEmail: Send EmailPhone: 09650213330Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/oncology
